|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | NY-ES()-I is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses 显示文摘 | van Rhee F Szmania SM Zhan F | 2005 | Blood2005，105，10： | 1 |
| 2 | Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation显示文摘 | Shi J Tricot G Szmania S | 2008 | Br J Haematol2008，143，5： | 1 |
| 3 | NY-ESO-1 is highly expressed Jn poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses显示文摘 | Van Rhee F Szmania SM Zhan F | 2005 | Blood2005，105，： | 1 |
| 4 | Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma显示文摘 | Szmania S Gnjatic S Tricot G | 2007 | Immunother2007，30，8： | 1 |
| 5 | Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma显示文摘 | BatchuRB Moreno AM Szmania SM | 2005 | Cancer Res2005，65，10： | 1 |
| 6 | Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman disease and is associated with increased soluble interleukin - 6 receptor levels 显示文摘 | Stone K Woods E Szmania SM | 2013 | PLoS One2013，8，54： | 1 |
| 7 | Infusion of haplo- identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation显示文摘 | SHI J TRICOT G SZMANIA S | 2008 | Br J Haematol2008，143，5： | 1 |
| 8 | Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma显示文摘 | van Rhee F Szmania SM Dil on M | | 0，，09： | 1 |
| 9 | Castleman Disease in the 21st Century: An Update on Diagnosis, Assessment, and Therapy 显示文摘 | van Rhee F Stone K Szmania S | 2010 | Clin Adv Hematol Oncol2010，8，7： | 1 |
| 10 | Highly activated and expanded natural killer cells for multiple myeloma immunotherapy显示文摘 | GARG T K SZMANIA S M KHAN J A | 2012 | Haematologica2012，97，9： | 1 |
| 11 | Castleman disease in the 21st century:an update on diagnoseis,assessment,and therapy显示文摘 | Van Rhee F Stone K Szmania S | | 0，，： | 1 |
| 12 | Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy显示文摘 | van RHEE F STONE K SZMANIA S | 2010 | Clin Adv Hematol Oncol2010，8，7： | 1 |
| 13 | Combinatorial eitleacy cff anti- CS1 monodonal antibody dotuzumab (HuLuc63) and bortezomib against multiple myeloma 显示文摘 | van Rhee F Szmania S M Dillon Met d | 2009 | Mol Cancer Ther2009，8，9： | 1 |
| 14 | Casfleman disease in the 21st century : an update on diagnosis, assessment, and therapy显示文摘 | van Rhee F Stone K Szmania S | 2010 | Clin Adv Hematol Oneo12010，8，7： | 1 |
| 15 | NY-ESO- 1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses 显示文摘 | van Rhee F Szmania SM Zhan F | 2005 | Blood2005，105，10： | 1 |
| 16 | Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation显示文摘 | Shi J Tricot G Szmania S | 2008 | Br J Haematol2008，143，5： | 1 |
| 17 | Profile of elotuzumab and its potential in the treatment of multiple myeloma显示文摘 | LIU YC SZMANIA S van RHEE F | 2014 | Blood Lymphat Cancer2014，2014，4： | 1 |
| 18 | Castleman dis-ease in the 21st century : an update on diagnosis,assessment,and therapy 显示文摘 | VAN RHEE F STONE K SZMANIAS | 2010 | Clin Adv Hematol Oncol2010，8，7： | 1 |
| 19 | Castleman dis- ease in the 21st century: an update on diagnosis, assessment, and therapy显示文摘 | VAN RHEE F STONE K SZMANIA S | 2010 | Clin Adv Hematol Oncol2010，8，7： | 1 |
| 20 | Infusion of haplo-identical killer im- munoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation显示文摘 | Shi J Tricot G Szmania S | 2008 | Br J Haematol2008，143，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员